Reporting on the science, the supply chain, and the business underneath the peptide market. Every piece carries its references.
We graded vendors on one axis only: the quality documents they actually publish. Named labs, real accession numbers, measured fill — or nothing.
Purity is one number. Identity, net content, endotoxin, and microbial screening are the ones most certificates quietly skip. The five-measure checklist, step by step.
Nearly every vial on the US market starts as bulk API from a small set of overseas synthesizers. FDA's Import Alert 66-80 now detains GLP-1 shipments by default — unless the maker is one of 19 green-listed firms worldwide. Here is how to check a supplier yourself.
The phase 2 numbers everyone quotes, what the phase 3 program still has to prove, and where the hype outruns the data.
Roughly a quarter to a third of the weight lost on GLP-1 agonists can be lean mass. The trial data, the resistance-training counterweight, and the protein math.
Peptide vendors live outside the mainstream payment rails. What that means for you — and what a crypto-only checkout is telling you.
Shortage rules built the compounded GLP-1 market and shortage rules are unwinding it. Where telehealth, 503A pharmacies, and research-use vendors actually stand right now.
The most-searched healing peptide on the market rests almost entirely on animal data. What the studies show, what they don't, and why WADA bans it anyway.
USP <71> sterility, USP <85> endotoxin, and PCR microbial screens are three different tests. Most vendors run one of them at most — and the word "tested" hides the difference.